Time-course analysis of serum hepcidin, iron and cytokines in a C282Y homozygous patient with Schnitzler's syndrome treated with IL-1 receptor antagonist.

Haematologica 2009 Sep 16;94(9):1297-300. Epub 2009 Jul 16.

Department of Clinical Chemistry, 441 Radboud University, Nijmegen Medical Center, Nijmegen, The Netherlands.

It is currently unknown if the increase of the hepatic iron regulatory hormone hepcidin during inflammation in man depends on an intact HFE-protein. Here we describe the temporal relationship of serum hepcidin, serum iron and cytokines in a patient with HFE-related (C282Y homozygous) hereditary hemochromatosis who was treated for an auto-inflammatory condition, i.e. variant Schnitzler's syndrome, with the potent anti-inflammatory cytokine inter-leukin-1 receptor antagonist (IL-1ra, anakinra). The patient had bouts of fever with peaking serum IL-6 concentrations followed by peaking serum hepcidin levels, while serum iron was low. Upon treatment, these peaks disappeared and hepcidin levels became non-detectable, consistent with HFE deficiency. In conclusion, this in vivo human model: i) supports the importance of an HFE-independent IL-6-hepcidin axis in the development of hypoferremia and anemia of inflammation; and ii) suggests that chronic inflammation protects patients with HFE-related hereditary hemochromatosis from iron accumulation.

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2009.005975DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2738724PMC
September 2009
10 Reads

Publication Analysis

Top Keywords

serum hepcidin
12
schnitzler's syndrome
8
c282y homozygous
8
hepcidin levels
8
receptor antagonist
8
serum iron
8
hereditary hemochromatosis
8
iron cytokines
8
peaking serum
8
serum
6
iron
5
hepcidin
5
syndrome potent
4
development hypoferremia
4
variant schnitzler's
4
condition variant
4
potent anti-inflammatory
4
inter-leukin-1 receptor
4
il-6-hepcidin axis
4
cytokine inter-leukin-1
4

Similar Publications